JZ

Johannes Zanzinger

Boehringer Ingelheim Venture Fund

Ulm, Baden-Württemberg

Investor
VC

Invests in

Stages:

Seed

Locations:

Germany

  • Min Investment:

    $3,250,000.00

  • Max Investment:

    $17,000,000.00

  • Target Investment:

    $8,500,000.00

Skills

Business Development
Collaborative R&D
Strategic Planning
Risk Assessment
Pharmacology
Drug Discovery
Clinical Research
Clinical Development
Drug Development
Technology Transfer
Biopharmaceuticals
Life Sciences
Oncology
Lifesciences
R&D
Pharmaceutical Industry
Metabolism
Biochemistry
Biotechnology

Education

Investments

DiogenX

Seed

Total Funding: $42M

Centauri Therapeutics

Series A

Total Funding: $33M

Work Experience

Ulm University

2011

  • Professor (apl) of Physiology

    2011

Centauri Therapeutics Limited

2022

  • Member Board Of Directors

    2022

DiogenX

2020

  • Member Board Of Directors

    2020

HepaRegeniX GmbH

2019

  • Member Board Of Directors

    2019

Boehringer Ingelheim

2002

  • Investor @ BI Venture Fund

    2019

  • Global Head, Business Development & Licensing CardioMetabolic Diseases

    2009 - 2019

  • Head, Licensing Metabolic Diseases

    2005 - 2009

  • Senior Principal Scientist, R&D Coordination

    2002 - 2005

AgomAb Therapeutics

2021 - 2023

  • Board Observer

    2021 - 2023

EYEVENSYS

2019 - 2023

  • Member Board Of Directors

    2019 - 2023

Metabomed Ltd.

2020 - 2021

  • Member Board Of Directors

    2020 - 2021

Pfizer

1999 - 2002

  • Senior Principle Scientist

    1999 - 2002

    Discovery Research, in vivo Pharmacology

University of Heidelberg

1993 - 1999

  • Associate Professor of Physiology

    1993 - 1999